Cancers of the Head and Neck Clinical Trial
Official title:
Initial Evaluation of Anti-1-amino-F-18 Flurocyclobutane-1carboxylic Acid (Anti-18F-FACBC) in the Assessment of Head and Neck Cancer: A Pilot Study.
The purpose of this study is to assess a relatively new PET (Positron emission tomography)
radiotracer called FACBC in the assessment of head and neck cancer. FDG (Flourine
Deoxyglucose) is currently used for PET imaging, but has limitations in head and neck cancer.
These limitations include problems with specificity, high background uptake from normal
structures, difficulty delineating intracranial invasion, and the need to wait several weeks
after chemotherapy and radiation before imaging. As an amino acid radiotracer, rather than a
glucose radiotracer, FACBC overcomes some of these limitations. FACBC does not yet have FDA
(Food and Drug Administration) approval, but does show promise in initial work in patients
with prostate cancer and brain tumors. Dosimetry work on FACBC has been performed at Emory.
Our study is a pilot study looking at 10 patients with a new diagnosis of biopsy proven
squamous cell carcinoma of the oral cavity who will be able to go on to definitive surgical
resection (ie, surgery without preceding chemotherapy or radiation). Patients must have
pre-surgical imaging, either with a contrast enhanced CT, FDG PET, or MRI. Patients who
consent to participate will receive one FACBC PET/CT of the neck, which will require a low
dose "transmission" CT of the neck, an intravenous injection of the radiotracer, and imaging
of the neck that will last up to 1 hour. Patients will have to lie still during the imaging
time. Total participation time including set up should be less than 90 minutes. Imaging
results will be analyzed and compared with conventional imaging as well as the surgical
pathology results
n/a